Legal Representation
Attorney
Douglas R. Wolf
USPTO Deadlines
Next Deadline
338 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20201124)
Due Date
November 24, 2026
Grace Period Ends
May 24, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 24, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Mar 19, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Nov 24, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 22, 2020 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 21, 2020 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 21, 2020 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 6, 2020 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 20, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 6, 2020 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Apr 29, 2020 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 28, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 3, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 3, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 12, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 30, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 29, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 29, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 29, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 9, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 8, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 15, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 14, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 3, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders
First Use Anywhere:
Aug 31, 2020
First Use in Commerce:
Aug 31, 2020
Additional Information
Design Mark
The mark consists of a series of generally hexagonal shaded polygons forming a swirl with a shaded circle at the top of the swirl, with the shapes being colored dark orange, orange, yellow, green, turquoise, dark turquoise, light blue, blue, navy, and purple.
Color Claim
The color(s) dark orange, orange, yellow, green, turquoise, dark turquoise, light blue, blue, navy, and purple is/are claimed as a feature of the mark.
Classification
International Classes
005